Skip to main content
PMC home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2009 Jul 9;24(2):137–141. doi: 10.1007/s12291-009-0025-y

MTHFR (Ala 222 Val) polymorphism and AMI in patients with type II diabetes mellitus

T Angeline 1,✉, G Thiruvarutselvi 1, W Isabel 1, Rita Mary Aruna 2, Rama Devi 3, Nirmala Jeyaraj 1
PMCID: PMC3453219  PMID: 23105822

Abstract

The prevalent Ala222Val single nucleotide polymorphism of the MTHFR gene has been shown to be associated with type II diabetes. The objective of the present study was to find out whether there is genetic predisposition for development of acute myocardial infarction in type II diabetes mellitus among South Indian Tamil population. PCR-based restriction enzyme analysis was performed in DNA isolated from 120 acute myocardial infarction patients with diabetes mellitus and 100 non diabetic healthy individuals with no documented cardiovascular diseases. The results indicate that the MTHFR 677TT genotype is absent in both case and controls. The MTHFR 677CT genotype was observed among 32 (26.7 %) cases and 20 (20%) controls and the MTHFR 677CC genotype among 88 (73.3%) cases and 80 (80%) controls. The allelic frequencies were in accordance to Hardy Weinberg equilibrium. There was no statistical difference in genotype distribution between cases and controls. In conclusion, we suggest that the analysis of MTHFR genotyping for C677T polymorphism alone need not be considered to find out whether there is genetic predisposition for development of acute myocardial infarction in type II diabetes mellitus among South Indian Tamil population.

Key Words: MTHFR gene, Type II diabetes, Polymorphism, Genetic predisposition, Acute Myocardial Infarction

Full Text

The Full Text of this article is available as a PDF (114.2 KB).

References

  • 1.Audelin M.C., Genest J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis. 2001;159:497–511. doi: 10.1016/S0021-9150(01)00531-7. [DOI] [PubMed] [Google Scholar]
  • 2.Ozmen B., Ozmen D., Turgan N., Habif S., Mutaf I., Bayindir O. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Lab Sci. 2002;32(3):279–286. [PubMed] [Google Scholar]
  • 3.Chico A., Perez A., Cordoba A., Arcelus R., Carreras G., Leiva A., Gonzalez-Sastre F., Blanco-Vaca F. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease. Diabetologia. 1998;41:684–693. doi: 10.1007/s001250050969. [DOI] [PubMed] [Google Scholar]
  • 4.Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., Heine R.J., Stehouwer C.D. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133–138. doi: 10.1161/01.atv.18.1.133. [DOI] [PubMed] [Google Scholar]
  • 5.Angeline T., Aruna R. M., Ramadevi K., Mohan G., Nirmala J. Homocysteine status and acute myocardial infarction among Tamilians. Ind J Clin Biochem. 2005;20(1):18–20. doi: 10.1007/BF02893035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Angeline T, Nirmala J, Tsongalis GJ. MTHFR Gene polymorphisms, B-vitamins and hyperhomocystinemia in young and middle-aged acute myocardial infarction patients. Exp Mol Pathol 2007; 227–233. [DOI] [PubMed]
  • 7.Spotila L.D., Jacques P.F., Berger P.B., Ballman K.V., Ellison R.C., Rozen R. Age dependence of the influence of Methylene tetrahydrofolate reductase genotype on plasma homocysteine level. Am J Epidemiol. 2003;158:871–877. doi: 10.1093/aje/kwg234. [DOI] [PubMed] [Google Scholar]
  • 8.Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., Heijer M., Kluijtmans L.A., Heuvel L.P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  • 9.Friedman G., Goldschmidt N., Friedlander Y., Ben-Yehuda A., Selhub J., Babaey S., Mendel M., Kidron M., Bar-On H. A common mutation A1298C in human methylenetetrahydrofolate reductase gene, Association with plasma total homocysteine and folate concentrations. Am Soc Nutr Sci. 1999;129:1656–1661. doi: 10.1093/jn/129.9.1656. [DOI] [PubMed] [Google Scholar]
  • 10.Crott J.W., Mashiyama S.T., Ames B.N., Fenech M.F. Methylenetetrahydrofolate reductase C677T polymorphism does not alter folic acid deficiency-induced Uracil incorporation into primary human lymphocyte DNA in vitro Cancer. Epidemiol Biomarkers Prev. 2001;22:1019–1025. doi: 10.1093/carcin/22.7.1019. [DOI] [PubMed] [Google Scholar]
  • 11.Kluijtmans L.A., Heuvel L.P., Boers G.H., Frosst P., Stevens E.M., Oost B.A., et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35–41. [PMC free article] [PubMed] [Google Scholar]
  • 12.Morita H., Taguchi J., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032–2036. doi: 10.1161/01.cir.95.8.2032. [DOI] [PubMed] [Google Scholar]
  • 13.Neugebauer S., Baba T., Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet. 1997;349:473–474. doi: 10.1016/S0140-6736(05)61185-3. [DOI] [PubMed] [Google Scholar]
  • 14.Sambrook J, Russell DW. Molecular cloning, A laboratory manual, 3rd ed. Cold Spring Harbor Laboratory 2001; 5.1–5.86.
  • 15.Angeline T., Nirmala J., Granito S., Tsongalis G.J. Prevalence of MTHFR gene polymorphisms (C677T and A1298C) among Tamilians. Exp Mol Pathol. 2004;77(2):85–88. doi: 10.1016/j.yexmp.2004.04.006. [DOI] [PubMed] [Google Scholar]
  • 16.Dekov V., Whincup P., Papacosta O., Ebrahim S., Lennon L., Ueland P.M., Refsum H., Humphries S.E., Gudnason V. The effect of the C677T and A1298C polymorphism in the Methylene tetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British Regional Heart study. Atherosclerosis. 2001;154:659–666. doi: 10.1016/S0021-9150(00)00522-0. [DOI] [PubMed] [Google Scholar]
  • 17.Robien K., Ulrich C.M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A Human Genome Epidemology Review minireview. Am J Epidemiol. 2003;157:571–582. doi: 10.1093/aje/kwg024. [DOI] [PubMed] [Google Scholar]
  • 18.Zetterberg H., Regland B., Palmér M., Ricksten A., Palmqvist L., Rymo L., Arvanitis D.A., Spandidos D.A., Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet. 2002;10:113–118. doi: 10.1038/sj.ejhg.5200767. [DOI] [PubMed] [Google Scholar]
  • 19.Devi R.R., Govindaiah V., Ramakrishna G., Naushad S.M. Prevalence of methylene tetrahydrofolate reductase polymorphism in South Indian population. Curr Sci. 2004;89(3):440–443. [Google Scholar]
  • 20.Isotalo P.A., Wells G.A., Donnelly J.G. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms, An examination of C677T and A1298C mutations. Am J Hum Genet. 2000;67:986–990. doi: 10.1086/303082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Maeda M., Yamamoto I., Fukuda M., Nishida M., Fujitsu J., Nonen S., et al. MTHFR Gene Polymorphism as a Risk Factor for Diabetic Retinopathy in Type 2 Diabetic Patients without Serum Creatinine Elevation. Diabetes Care. 2003;26:547–548. doi: 10.2337/diacare.26.2.547. [DOI] [PubMed] [Google Scholar]
  • 22.Ksiazek P., Bednarek-Skublewska A., Buraczynska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit. 2004;10(2):BR47–BR51. [PubMed] [Google Scholar]
  • 23.Yilmaz H., Agachan B., Ergen A., Karaalib Z.E., Isbir T. Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 2004;37(2):234–238. doi: 10.5483/bmbrep.2004.37.2.234. [DOI] [PubMed] [Google Scholar]
  • 24.Agullo-Ortuno M.T., Albaladejo M.D., Parra S., Rodriguez-Manotas M., Fenollar M., Ruiz-Espejo F., Tebar J., Martinez P. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta. 2002;326:105–112. doi: 10.1016/S0009-8981(02)00287-5. [DOI] [PubMed] [Google Scholar]
  • 25.Shpichinetsky V., Raz I., Friedlander Y., Goldschmidt N., Wexler I.D., Ben-Yehuda A., Friedman G. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr. 2000;130(10):2493–2497. doi: 10.1093/jn/130.10.2493. [DOI] [PubMed] [Google Scholar]
  • 26.Sun J., Xu Y., Zhu Y., Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract. 2004;64(3):185–190. doi: 10.1016/j.diabres.2003.10.022. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES